Dow Jones
35.430,42 +13,44 (+0,04%) Nasdaq
14.258,49 -23,27 (-0,16%) Nikkei 225
33.321,22 -87,17 (-0,26%) EUR/USD
1,0975 -0,0024 (-0,22%) Bitcoin EUR
34.439,84 -189,32 (-0,55%) CMC Crypto 200
778,64 -6,86 (-0,87%)
Sarepta Therapeutics, Inc. (0L35.L)
| Chiusura precedente | 82,17 |
| Aperto | 82,13 |
| Denaro | 0,00 x N/D |
| Lettera | 0,00 x N/D |
| Min-Max giorno | 81,99 - 83,28 |
| Intervallo di 52 settimane | 55,68 - 159,77 |
| Volume | |
| Media Volume | 579 |
| Capitalizzazione | 66,786M |
| Beta (5 anni mensile) | 0,95 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -4,28 |
| Prossima data utili | 26 feb 2024 - 01 mar 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | N/D |
GlobeNewswireSarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., Jan. 31, 2023 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on January 31, 2022 that were previously approved by the Compensation Committee of its Board of Directors under Sarepta’s 2014 Employment Commencement Incentive Plan, as a material inducement to employment to 40 individuals hired by Sarepta in January 2023. The equity awards were approved in accordance with Nasdaq Listing
- GlobeNewswire
Sarepta Therapeutics Reports Preliminary* Fourth Quarter and Full-Year 2022 Net Product Revenues
- The Company expects to exceed 2022 full-year guidance for net product revenues - Preliminary net product revenues for the fourth quarter and full-year 2022 are expected to total $235.5 million and $843.3 million, respectively - Preliminary year-end 2022 cash balance of approximately $2.0 billion CAMBRIDGE, Mass., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported preliminary* fourth quarter and
- GlobeNewswire
Sarepta Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will present at the 41st Annual J.P. Morgan Healthcare Conference in San Francisco, California on Monday, January 9, 2023 at 1:30 p.m. E.T. / 10:30 a.m. P.T. Following the presentation there will be a Q&A session starting at 1:50 p.m. E.T. / 10:50 a.m. P.T. The presentation will be webcast live under the E
